Takizawa, Tsubasa
Kitano, Takahiro
Iijima, Masahiro
Togo, Kanae
Yonemoto, Naohiro
Funding for this research was provided by:
Pfizer Japan Inc
Article History
Received: 28 December 2023
Accepted: 19 January 2024
First Online: 8 February 2024
Declarations
:
: The study protocol was approved by the Institutional Review Board held by MINS (a specified nonprofit organization) on April 5, 2023 (647d88a729cc751d1e1ea75c.pdf (npo-mins.com). It was based on anonymized personal information following privacy laws, and obtaining informed consent from patients was not required. The principles outlined in the Declaration of Helsinki were followed.
: Not applicable.
: TT is a consultant/advisor and/or serves on an advisory board for Pfizer, Eli Lilly, Otsuka, Amgen, and Teijin and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and grant from Pfizer and research funding from Eli Lilly and Tsumura outside the submitted work. MI, TK, KT, and NY are employees of Pfizer Japan (Tokyo, Japan). MI, KT, and NY are shareholders of Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.